Jank, Paul
Leichsenring, Jonas
Kolb, Svenja
Hoffmann, Inga
Bischoff, Philip
Kunze, Catarina Alisa
Dragomir, Mihnea P.
Gleitsmann, Moritz
Jesinghaus, Moritz
Schmitt, Wolfgang D.
Kulbe, Hagen
Sers, Christine
Stenzinger, Albrecht
Sehouli, Jalid
Braicu, Ioana Elena
Westhoff, Christina
Horst, David
Denkert, Carsten
Gröschel, Stefan
Taube, Eliane T.
Funding for this research was provided by:
Charité–Universitätsmedizin Berlin and the Berlin Institute of Health (BIH-Charité Junior Clinical Scientist Program, BIH-Charité Junior Clinical Scientist Program)
DKTK Berlin (Young Investigator Grant 2022)
Berliner Krebsgesellschaft (DRFF202204)
Transcan (Grant 2014-121, Grant 2014-121)
Charité - Universitätsmedizin Berlin
Article History
Received: 23 March 2023
Accepted: 16 July 2023
First Online: 31 July 2023
Declarations
:
: Ethical approval was given by the ethics committee of Charité Universitätsmedizin Berlin (EA1/051/18). The study was performed in accordance with the Declaration of Helsinki and with local ethical guidelines (ethic committee approval number EA1/051/18) and is supported by the TRANSCAN-2 project (grant no.: 2014–121). Written consent was given within treatment agreement of the Charité University-Hospital Berlin. Treatment Agreement forms from 2005 and 2021 are included in the supplementary material.
: Not applicable.
: PJ reports stock ownership from Myriad Genetics Inc. CAK reports Honoraria from Ipsen. CS reports honoraria, consulting or advisory role and travel, accomodations, exprenses from Amgen. IEB reports honoraria from MSD, AstraZeneca, GSK, CLOVIS, RochePharma and consulting or advisory role from SD, AstraZeneca, GSK, CLOVIS, NOGGO. CD reports consulting fees or advisory board from AstraZeneca, Daiichi Sankyo, Lilly, Molecular Health, MSD Oncology, Roche; ownership interests from Sividon Diagnostics and receipt of intellectual property/ patent holder, royalty from VMScope. JL, SV, IH, PB, MPD, MG, MJ, WDS, HK, AS, JS, IEB, CW, DH, SG, ETT declare no competing interests.